Revium Rx COO, President and Director Inna Martin resigns due to differences in expectations

Revium Rx.

Inna Martin resigned as Director, COO, and President effective June 16, 2026, due to differences in expectations with the company.
Separation agreement: employment and consultancy with Revium Ltd. ends Sep 10, 2026; vested stock option exercise period extended to Sep 30, 2028 for up to 2,440,000 shares.
Shares and options subject to sale restrictions per Separation Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.